SPOP and adenocarcinoma: Further support for this hypothesis comes from Blattner et al. (2017), where expression of SPOP F133V, a mutation very similar to the one we demonstrated caused changes in the AR cistrome (Fig. 3), did not by itself cause adenocarcinoma in the mouse prostate, but greatly accelerated the development of cancer when coupled with Pten loss.